Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 3/20 | 0.43 |
| ▸ | F10 | P00742 | 3/20 | 0.43 |
| ▸ | PLAU | P00749 | 3/20 | 0.43 |
| ▸ | PLAT | P00750 | 3/20 | 0.43 |
| ▸ | PLG | P00747 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28779396 | 0.84 | TDP1 (0.43) | CYP1A2F2PLAUKMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL28779394 | 0.83 | TDP1 (0.42) | CYP1A2F2PLAUKMT2ANPC1 | |
| SCHEMBL19526332 | 0.81 | KMT2A (0.59) | F2F10PLAUPLATPLG | |
| SCHEMBL377804 | 0.81 | MYC (0.58) | CYP1A2KMT2ANPC1RAB9APOLB | |
| SCHEMBL10955222 | 0.81 | GABRP (0.41) | CYP1A2F2F10PLAUPLAT | |
| SCHEMBL7348784 | 0.80 | SMN1; SMN2 (0.50) | PLAUKMT2ANPC1RAB9APOLB | |
| SCHEMBL7978757 | 0.80 | KLK1 (0.48) | F2F10PLAUPLATPLG | |
| SCHEMBL2390452 | 0.80 | ALDH1A1 (0.55) | CYP1A2KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL15154757 | 0.79 | NPC1 (0.58) | CYP1A2KMT2ANPC1RAB9APOLB | |
| Hydrochloric Acid SCHEMBL2512014 | 0.78 | ALDH1A1 (0.54) | CYP1A2KMT2ANPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765076-B2 | Aurora kinase inhibitors for inhibiting mitotic progression | MILLENIUM PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20150166545-A1 | Aurora Kinase Inhibitors for Inhibiting Mitotic Progression | MILLENNIUM PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8178516-B2 | Composition of 4-guanidinobenzoic acid HCl, a co-agent suitable for systemic administration solely via the oral route, antioxidants, vitamins, metabolites | Sylvan Labs, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | disclosed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | disclosed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | disclosed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | CYP1A2 338/4885F2 500/4885F10 1594/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | CYP1A2 397/4885F2 510/4885F10 1462/4885 |
| US-20150166545-A1 | Aurora Kinase Inhibitors for Inhibiting Mitotic Progression | AURKC, AURKA, AURKB | CYP1A2 4514/4885F2 4820/4885F10 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.